A controlled study of danazol for the treatment of karyotypically normal spontaneous premature ovarian failure

To determine if the immunomodulatory and gonadotropin-suppressing properties of danazol would improve follicle function or ovulation rates in patients with karyotypically normal spontaneous premature ovarian failure. Prospective, double-blind, crossover trial. Tertiary care research institution. Two intervention phases lasting 4months each: one phase during which patients received a standardized estrogen and progestin replacement regimen and one phase during which each patient received a twice daily 400mg oral dose of danazol. Fifty-two patients with karyotypically normal spontaneous premature ovarian failure ranging in age from 21 to 39years. We measured serum E2 and P levels weekly during the 2months after each intervention. We defined a serum E2>50pg/mL (184 pmol/L) as evidence of ovarian follicle function and a P>3.0ng/mL (9.5nmol/L) as evidence for ovulation. Of the 46 patients who completed the study, danazol did not significantly enhance ovarian follicle function or the chance of ovulation. Eight patients ovulated after danazol and four patients ovulated after estrogen and progestin. The power to detect a 30% and a 5% ovulation success rate with therapy was 0.80 and 0.90, respectively. Overall, 30 of 46 women (65%) demonstrated ovarian follicle function and 10 women (21%) ovulated. We were unable to demonstrate a statistically significant benefit from the immunomodulatory and gonadotropin-suppressing effects of danazol in patients with karyotypically normal spontaneous premature ovarian failure. These patients often have spontaneous remission. Thus, controlled studies are required to determine the effectiveness of treatments for this condition.